IFITM1
IFITM1 (interferon induced transmembrane protein 1, also known as 9-27, CD225, DSPA2a and IFI17) is an interferon-induced antiviral protein that restricts the entry of diverse viruses into host cells. It also contributes to cell adhesion, growth control and migration. Browse Assay Genie's current range of IFITM1 research reagents below, or read on for the biology behind the target.
IFITM1 is an interferon-induced antiviral protein that inhibits the entry of viruses into the host cell cytoplasm. It permits endocytosis but prevents the subsequent viral fusion and release of viral contents into the cytosol. Reported activity covers multiple viruses, including influenza A virus, SARS-CoV and SARS-CoV-2, Marburg virus, Ebola virus, Dengue virus, West Nile virus, HIV-1 and hepatitis C virus (HCV). It can inhibit influenza virus hemagglutinin-mediated entry, Marburg and Ebola virus GP1,2-mediated entry, and SARS-CoV and SARS-CoV-2 S protein-mediated entry, and it also inhibits SARS-CoV-2 S protein-mediated syncytia formation.
Beyond virology, IFITM1 is implicated in cell adhesion and in the control of cell growth and migration. It plays a key role in the antiproliferative action of IFN-gamma, either by inhibiting ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. It also acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed virion for lysosomal degradation. IFITM2 and IFITM3 show anti-HCV activity that may complement that of IFITM1 by inhibiting late stages of HCV entry, possibly by trapping the virion in the endosomal pathway and directing it to the lysosome.
The IFITM1 gene belongs to the interferon-induced transmembrane protein family, which contains five members; IFITM1, IFITM2 and IFITM3 belong to the CD225 superfamily, also called the dispanins. The protein is found at the cell membrane and the lysosome membrane. The HGNC lists it among CD molecules, and its previous name was interferon induced transmembrane protein 1 (9-27). A mouse ortholog, Ifitm1, is recorded.
IFITM1 is an interferon-induced factor that blocks viral fusion and release of contents into the cytosol, making it a model for intrinsic antiviral restriction.
It inhibits entry mediated by influenza hemagglutinin, Ebola and Marburg GP1,2 and SARS-CoV-2 S protein, supporting studies of virus-host membrane fusion.
In hepatocytes IFITM1 targets endocytosed HCV virions for lysosomal degradation, alongside IFITM2 and IFITM3, which makes it relevant to HCV entry research.
IFITM1 contributes to IFN-gamma antiproliferative action via ERK inhibition or p53-dependent G1 arrest, and positively regulates osteoblast differentiation.
IFITM1 is an interferon-induced antiviral protein that stops viruses from releasing their contents into the cytosol after endocytosis. It is also implicated in cell adhesion, growth and migration, mediates part of the antiproliferative effect of IFN-gamma, and promotes osteoblast differentiation.
IFITM1 is also known as 9-27, CD225, DSPA2a and IFI17, and its previous HGNC name was interferon induced transmembrane protein 1 (9-27). It belongs to the CD225/Dispanin family, alongside IFITM2 and IFITM3.
A mouse ortholog, Ifitm1, is recorded. Human IFITM1 is active against influenza A virus, SARS coronaviruses, Ebola, Marburg, Dengue, West Nile, HIV-1 and HCV. Check the datasheet of any product for its validated reactivity.
Other members of the IFITM family, which also restrict viral entry and complement IFITM1 activity against HCV.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P13164; product specifications from Assay Genie datasheets.